comparemela.com

Latest Breaking News On - Distribution channel retail pharmacies drug stores - Page 3 : comparemela.com

Non-Hodgkin s Lymphoma Drives The Rituximab Biosimilars Industry - Brazil Business Today

Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change The Business Research Company’s Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change LONDON, GREATER LONDON, UK, February 8, 2021 /EINPresswire.com/ New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The rising prevalence of non-Hodgkin’s lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin’s lymphoma is a cancer that starts in white blood cells (lymphocytes) that are part of the body’s immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell NHL and adult patients with CD20-positive. According to the National Library of Medicine’s statistics, non-Hodgkin lymphoma was ranked as the 5th to 9th

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.